Trial Profile
Expanded access study of satraplatin plus prednisone in patients with hormone refractory prostate cancer (HRPC) previously treated with unlimited cytotoxic chemotherapy regimen (SPERA)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Satraplatin (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SPERA
- 08 May 2012 Actual patient number is 344 according to ClinicalTrials.gov.
- 08 May 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 08 May 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.